3-deazauridine and Rectal-Neoplasms

3-deazauridine has been researched along with Rectal-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for 3-deazauridine and Rectal-Neoplasms

Article	Year
Phase II study of 3-deazauridine in advanced colorectal adenocarcinoma. American journal of clinical oncology, 1982, Volume: 5, Issue:1 A phase II study of 3-deazauridine (DAUR) showed poor activity in previously treated patients with advanced colorectal adenocarcinoma. There were no responses among 15 patients treated on a dose schedule of 1200 mg/m2/day for 5 days repeated at 3-week intervals. Toxicity included mild nausea and vomiting, occasional mucositis, diarrhea, and dizziness. A minimal degree of myelosuppression was observed. Topics: 3-Deazauridine; Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Digestive System; Drug Evaluation; Female; Humans; Male; Middle Aged; Rectal Neoplasms; Uridine	1982

Article

Year

Phase II study of 3-deazauridine in advanced colorectal adenocarcinoma.

American journal of clinical oncology, 1982, Volume: 5, Issue:1

A phase II study of 3-deazauridine (DAUR) showed poor activity in previously treated patients with advanced colorectal adenocarcinoma. There were no responses among 15 patients treated on a dose schedule of 1200 mg/m2/day for 5 days repeated at 3-week intervals. Toxicity included mild nausea and vomiting, occasional mucositis, diarrhea, and dizziness. A minimal degree of myelosuppression was observed.

Topics: 3-Deazauridine; Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Digestive System; Drug Evaluation; Female; Humans; Male; Middle Aged; Rectal Neoplasms; Uridine

1982